Radiography
Volume 13 , Pages e73-e84 , December 2007

Ultrasmall superparamagnetic iron oxide enhanced MR imaging for lymph node metastases

Received 30 November 2006 ,Accepted 24 March 2007.

References 

  1. Bataskis JG. Squamous cell carcinoma of the oral cavity and the oropharynx. In:  Batsakis JG editors. Tumors of the head and neck: clinical and pathological considerations. 2nd ed.. Baltimore: Williams & Wilkins; 1979;p. 240–250
  2. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of nonsmall-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–261
  3. Witte CL, Williams WH, Witte JH. Lymphatic imaging (editorial). Lymphology. 1993;26:109–111
  4. Anzai Y, Brunberg JA, Lufkin RB. Imaging of nodal metastases in the head and neck. J Magn Reson Imaging. 1997;7:774–783
  5. Davis GL. Sensitivity of frozen section examination of pelvic lymph-node for metastatic prostate carcinoma. Cancer. 1995;76:661–666
  6. Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology. 1988;168:297–301
  7. Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology. 2003;228:777–788
  8. Bellin MF, Lebleu L. Meric JB Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography. Abdom Imaging. 2003;28:155–163
  9. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultra small super paramagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology. 1990;175:494–498
  10. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultra small super paramagnetic iron oxide: characterization of a new class of contrast agent for MR imaging. Radiology. 1990;175:489–493
  11. Hudgins PA, Anzai Y, Morris MR, Lucas MA. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol. 2002;23(4):649–656
  12. Sigal R, Vogl T, Casselman J, Moulin G, Veillon F, Hermans R, et al. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR)—results of a phase-III multicenter clinical trial. Eur Radiol. 2002;12:1104–1113
  13. Harishinghani MG, Saksena MA, Hahn PF, King B, Kim J, Torabi MT, et al. Ferumoxtraon-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization?. Am J Roentgenol. 2006;186:144–148
  14. Harisinghani MG, Dixon WT, Saksena MA, et al. MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10. Radiographics. 2004 May–Jun;24(3):867–878[Review]
  15. Anzai Y, McLachlan S, Morris M, Saxton R, Lufkin RB. Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck. AJNR Am J Neuroradiol. 1994;15:87–94
  16. Anzai Y, Prince MR. Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node, metastases in the head and neck cancer. J Magn Reson Imaging. 1997;7:75–81
  17. Lee AS, Weissleder R, Brady TJ, Wittenberg J. Lymph nodes: microstructural anatomy at MR imaging. Radiology. 1991;17(8):519–522
  18. Nishimura H, Taniagwa N, Hiramatsu M, Tatsumi Y, Matsuki M, Narabayashi I. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide. J Am Col Surg. 2006;202:604–611
  19. Bellin MF, Roy C, Kinkel K, Thoumas D, Zaim S, Vanel D, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles—initial clinical experience. Radiology. 1998;207:799–808
  20. Pannu HK, Wang KP, Borman TI, Bluemke DA. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent. J Magn Reson Imaging. 2000;12:899–904
  21. Koh DM, Brown G, Temple L, Raja A, Toomey P, Bett N, et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings—initial observations. Radiology. 2004;23:91–99
  22. Curvo-Semedo L, Diniz M, Migueis J, Juliao MJ, Martins P, Pinto A, et al. USPIO-enhanced magnetic resonance imaging for nodal staging in patients with head and neck cancer. J Magn Reson Imaging. 2006;24:123–131
  23. Carr I. Lymphatic metastasis Cancer. Metastasis Rev. 1983;2:307–317
  24. Tanoura T, Bernas M, Darkazanli A, Elam E, Unger E, Witte M, et al. MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis. AJR. 1992;159:875–881
  25. Anzai Y, Blackwell KE, Hirschowitz SL, Rogers JW, Sato Y, Yuh WT, et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology. 1994;192:709–715
  26. Nguyen BC, Stanford W, Thompson BH, Rossi NP, Kernstine KH, Kern JA, et al. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imaging. 1999;10:468–473
  27. Mack MG, Balzer JO, Straub R, Eichler K, Vogl TJ. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology. 2002;222:239–244
  28. Michel SC, Keller TM, Frohlich JM, Fink D, Caduff R, Seifert B, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology. 2002;225:527–536
  29. Stets C, Brandt S, Wallis F, Buchmann J, Gilbert FJ, Heywang-Kobrunner SH. Axillary lymph node metastases: a statistical analysis of various parameters in MRI with USPIO. J Magn Reson Imaging. 2002;16:60–68
  30. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491–2499
  31. Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology. 2004;233:449–456
  32. Keller TM, Michel SC, Frohlich J, Fink D, Caduff R, Marincek B, et al. USPIO-enhanced MRI for preoperative staging of gynecological pelvic tumors: preliminary results. Eur Radiol. 2004;14:937–944
  33. Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol. 2005;23:2813–2821
  34. Harishinghani MG, Saksena M, Ross RW, et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology. 2005 Nov;66(5):1066–1071
  35. Tatsumi Y, Tanigawa N, Nishimura H, Nomura E, Mabuchi H, Matsuki M, et al. Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10. Gastric Cancer. 2006;9:120–128
  36. Stadnik TW, Everaert H, Makkat S, Sacre R, Lamote J, Bourgain C. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging for axillary lymph node staing—initial findings. Eur Radiol. 2006;16:2153–2160
  37. Will O, Purkayastha S, Chan C, Athanasion T, Darzi AW, Gedroyc W, et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet. 2006 Jan;7(1):52–60
  38. Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False-positive and false-negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7(1):57–69
  39. Lopez R, Payoux P, Gantet P, Esquerre JP, Boutault F, Paoli JR. Multimodal image registration for localization of sentinel nodes in head and neck squamous cell carcinoma. J Oral Maxillofac Surg. 2004;62(12):1497–1504
  40. Hafner J, Schmid MH, Kempf W, Burg G, Kunzi W, Meuli-Simmen C, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol. 2004;150(4):677–686
  41. Chen SL, Iddings DM, Scheri RP, Bilchik AJ. Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J Clin. 2006;56(5):292–309
  42. Heesakkers RAM, Futterer JJ, Hovels AM, van den Bosch HC, Scheenen TW, Hoogeveen YZ, et al. Prostate cancer evaluation with ferumoxtran-10-enhanced T2*-weighted MR imaging at 1.5 and 3.0T: Early experience. Radiology. 2006;239:481–487

PII: S1078-8174(07)00037-5

doi: 10.1016/j.radi.2007.04.001

Radiography
Volume 13 , Pages e73-e84 , December 2007

Article Tools

* Image Usage & Resolution